Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia

Phase II trial of blinatumomab showing haematologic and molecular remissions in relapsed/refractory B-precursor ALL.

Publication · 2024-11-06

More detail is on the way.

Full content is being migrated into the new site. Reach out and a senior contact will send you a copy directly.

All white papers, case studies, publications and blogs.

Peer-reviewed and journal articles.

Talk to a senior contact about the work behind this.